利用凝血酶时间临床特征预测乳腺癌1-2个前哨淋巴结阳性状态下的非前哨淋巴结转移

IF 2.6 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-09-29 DOI:10.1080/14796694.2025.2565827

Gang Chen, Yuhan Bao, Yidan Wang, Jianqiao Cao, Chao Yu, Guangdong Qiao, Yizi Cong

{"title":"利用凝血酶时间临床特征预测乳腺癌1-2个前哨淋巴结阳性状态下的非前哨淋巴结转移","authors":"Gang Chen, Yuhan Bao, Yidan Wang, Jianqiao Cao, Chao Yu, Guangdong Qiao, Yizi Cong","doi":"10.1080/14796694.2025.2565827","DOIUrl":null,"url":null,"abstract":"Background: This study aims to investigate biomarkers for predicting non-SLN metastasis and tumor metastatic burden in patients with 1-2 positive sentinel lymph nodes (SLNs).Research design and methods: 581 patients with SLN metastasis were enrolled, and their blood biochemical indices and clinical information were tested and analyzed.Results: Among patients with 1-2 positive SLNs, the SLN positivity rate was higher in the non-SLN metastasis group than in the non-metastasis group. Additionally, thrombin time (TT) and fibrinogen (Fbg) levels were lower in the non-SLN metastasis group compared with the non-metastasis group, with ROC AUC = 0.712. Regarding tumor burden, among patients with 1-2 positive SLNs, the SLN positivity rate was significantly higher in those with metastasis lymph nodes (mLNs) ≥ 4 than in those with <4 mLNs, with ROC AUC = 0.727.Conclusions: The SLN positivity rate, TT, and Fbg may serve as potential biomarkers for non-SLN metastasis in patients with 1-2 positive SLNs. Additionally, the SLN positivity rate may serve as a potential biomarker for mLNs ≥ 4 in cases with 1-2 positive SLNs and in those with only 1 positive SLN.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":2.6000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prediction of non-sentinel lymph node metastasis using the clinical features of thrombin time under the status of 1-2 positive sentinel lymph node of breast cancer.\",\"authors\":\"Gang Chen, Yuhan Bao, Yidan Wang, Jianqiao Cao, Chao Yu, Guangdong Qiao, Yizi Cong\",\"doi\":\"10.1080/14796694.2025.2565827\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: This study aims to investigate biomarkers for predicting non-SLN metastasis and tumor metastatic burden in patients with 1-2 positive sentinel lymph nodes (SLNs).Research design and methods: 581 patients with SLN metastasis were enrolled, and their blood biochemical indices and clinical information were tested and analyzed.Results: Among patients with 1-2 positive SLNs, the SLN positivity rate was higher in the non-SLN metastasis group than in the non-metastasis group. Additionally, thrombin time (TT) and fibrinogen (Fbg) levels were lower in the non-SLN metastasis group compared with the non-metastasis group, with ROC AUC = 0.712. Regarding tumor burden, among patients with 1-2 positive SLNs, the SLN positivity rate was significantly higher in those with metastasis lymph nodes (mLNs) ≥ 4 than in those with <4 mLNs, with ROC AUC = 0.727.Conclusions: The SLN positivity rate, TT, and Fbg may serve as potential biomarkers for non-SLN metastasis in patients with 1-2 positive SLNs. Additionally, the SLN positivity rate may serve as a potential biomarker for mLNs ≥ 4 in cases with 1-2 positive SLNs and in those with only 1 positive SLN.\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"1-11\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2025.2565827\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2565827","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：本研究旨在探讨预测1-2个前哨淋巴结（sln）阳性患者的非sln转移和肿瘤转移负荷的生物标志物。研究设计与方法：选取581例SLN转移患者，对其血液生化指标及临床资料进行检测分析。结果：在1-2例SLN阳性患者中，非SLN转移组SLN阳性率高于非转移组。此外，非sln转移组凝血酶时间（TT）和纤维蛋白原（Fbg）水平低于非sln转移组，ROC AUC = 0.712。在肿瘤负荷方面，1-2个SLN阳性患者中，转移淋巴结≥4的患者SLN阳性率明显高于转移淋巴结≥4的患者。结论：SLN阳性率、TT和Fbg可能是1-2个SLN阳性患者非SLN转移的潜在生物标志物。此外，SLN阳性率可作为1-2个SLN阳性和1个SLN阳性的mln≥4的潜在生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Prediction of non-sentinel lymph node metastasis using the clinical features of thrombin time under the status of 1-2 positive sentinel lymph node of breast cancer.

Background: This study aims to investigate biomarkers for predicting non-SLN metastasis and tumor metastatic burden in patients with 1-2 positive sentinel lymph nodes (SLNs).

Research design and methods: 581 patients with SLN metastasis were enrolled, and their blood biochemical indices and clinical information were tested and analyzed.

Results: Among patients with 1-2 positive SLNs, the SLN positivity rate was higher in the non-SLN metastasis group than in the non-metastasis group. Additionally, thrombin time (TT) and fibrinogen (Fbg) levels were lower in the non-SLN metastasis group compared with the non-metastasis group, with ROC AUC = 0.712. Regarding tumor burden, among patients with 1-2 positive SLNs, the SLN positivity rate was significantly higher in those with metastasis lymph nodes (mLNs) ≥ 4 than in those with <4 mLNs, with ROC AUC = 0.727.

Conclusions: The SLN positivity rate, TT, and Fbg may serve as potential biomarkers for non-SLN metastasis in patients with 1-2 positive SLNs. Additionally, the SLN positivity rate may serve as a potential biomarker for mLNs ≥ 4 in cases with 1-2 positive SLNs and in those with only 1 positive SLN.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.